Published in final edited form as:

Fertil Steril. 2014 January ; 101(1): 14–19. doi:10.1016/j.fertnstert.2013.11.025.

Adult Somatic Cells to the Rescue: Nuclear Reprogramming and the Dispensability of Gonadal Germ Cells

Charles A. Easley IV¹, David R. Latov¹, Calvin R. Simerly^{2,3}, and Gerald Schatten^{2,3}

¹Laboratory of Translational Cell Biology, Department of Cell Biology, Emory University School of Medicine, Atlanta, GA 30322

²Department of Ob-Gyn-Repro Sci, University of Pittsburgh School of Medicine, Pittsburgh, PA 15108

³Magee Womens Research Institute, Pittsburgh Development Center, Pittsburgh, PA 15108

Summary

With advances in cancer therapies, survival rates in prepubescent patients have steadily increased. However a number of these surviving patients have been rendered sterile due to their rigorous oncological treatment regimens. In addition to cancer treatments, men and women, who are genetically fertile, can become infertile due to immune suppression treatments, exposure to environmental and industrial toxicants, and injury. Notwithstanding the great emotional burden from an inability to conceive a child with their partner, the financial burdens for testing and treatment are high and are rarely successful at treating these patients' sterility. Recent advances in pluripotent stem cell differentiation and the generation of patient-specific, induced pluripotent stem cells indicate that stem cell replacement therapies or *in vitro* differentiation followed by IVF may be on the horizon. Here, we discuss these recent advances, their relevance to treating male-factor and female-factor infertility, and what experimental procedures must be carried out in animal models before these exciting new treatments can be used in a clinical setting. The goal of this research is to generate functional gametes from no-greater starting material than a mere skin biopsy.

Keywords

infertility; stem cells; assisted reproductive technology; differentiation

© 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Contact Information: Gerald Schatten, Magee Womens Research Institute 204 Craft Ave B608, Pittsburgh, PA 15213, Tel- 412-641-2400, Fax- 412-641-2410, schattengp@upmc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

In previous decades, medical professionals were focused on treating cancers in prepubescent boys and girls to extend their lives with little concern over preserving patients' fertility. As cancer survival rates in adolescents have steadily increased over the last few decades¹⁻⁹, the focus has shifted to preserving fertility to enable these patients to produce offspring as adults³. However fertility preservation can be extended to any medical treatment that impacts fertility such as immune suppressant treatment which has been shown to cause permanent sterility in some male patients^{10,11}. While fertility preservation will ultimately impact future patients, patients previously sterilized by their medical treatments currently have no treatment options with which to produce their own genetic offspring.

For both male and female patients experiencing infertility, the current Assisted Reproductive Technology (ART) treatment options rely solely on the premise that both partners produce functional haploid gametes. For those couples where one partner is unable to produce a functional gamete (egg or sperm), no treatment options are available^{12,13}. Non-genetic factors that result in sterility or sub-fertility are injury, exposure to environmental and industrial toxicants, and medical interventions such as chemotherapies and immune suppressant treatments^{1,2,10,11,14}. For these patients, there are no cures for their infertility/sterility, and they are unable to conceive a child with their partner.

For patients unable to cryopreserve gametes prior to their sterilization, two stem cell treatment options are on the horizon. 1) spermatogonial stem cell (SSC) transplant and 2) patient-specific pluripotent stem cells differentiated into functional gametes. This review will briefly discuss SSC transplant but instead focus on the use of patient-specific pluripotent stem cells as a novel means for restoring fertility in sterile patients^{12,13,15}.

Spermatogonial Stem Cell Transplant

The most advanced "stem cell" treatment option for patients rendered sterile by high dose chemotherapies is spermatogonial stem cells (SSC) transplant. Here, pre-pubescent boys have testis-tissue biopsies prior to gonadotoxic chemotherapy and SSCs are isolated from the samples in a GMP (good medical practice) environment and cryopreserved for re-introduction post chemotherapy. Several animal model studies have shown the ability to re-introduce spermatogonial stem cells (SSCs) obtained from testis biopsies to restore fertility in sterilized animals,¹⁶⁻²¹ including primates²². This methodology is ideal for re-introducing a patients' own natural germline stem cells for recolonization of the testes and restoration of fertility. However, this method of fertility preservation only works if a testis biopsy is obtained prior to chemotherapy. There is a large patient population that was unable to bank SSCs prior to medical interventions that caused sterility and thus are unable to be treated with this exciting new option. Likewise, this method carries a risk of re-introducing cancer cells, although this risk has been reduced as Herman et al. have shown that approximately 99% of cancer cells can be removed by flow cytometry from a testis cell suspension²³. Furthermore, SSC re-colonization requires that the somatic environment of the testes must remain intact after the medical intervention. For patients with damaged somatic environments whereby the seminiferous tubules are unable to support SSC transplant due to

loss of Sertoli Cells or structural collapse of the tubules, this type of strategy is ineffective at curing a patient's infertility. In these cases, and for those patients who were unable to cryopreserve gametes or SSCs, no options are currently available to cure their infertility. However, future pluripotent stem cell options whereby functional gametes can be derived *in vitro* may be beneficial.

Pluripotent Stem Cell Treatment Options

Recent evidence by several labs has shown the ability of human, non-human primate, and mouse pluripotent stem cells to differentiate into VASA- and DAZL-expressing primordial germ cells (PGCs)²⁴⁻³⁷, precursor cells that contribute to gametogenesis in both males and females. Studies with mouse pluripotent stem cells have even shown the ability to make functional sperm^{30,38}. The recent work by Hayashi et. al. suggest that pluripotent stem cells can be differentiated into a PGC-like state then transplanted into a sterile mouse testis for re-colonization and the generation of functional haploid sperm cells³⁷. While PGCs have shown the limited capacity to re-colonize sterile testis in mammals other than rodents, the possibility exists that pluripotent stem cells can be differentiated into a lineage more suitable for re-colonization and restoration of spermatogenesis. In fact, we recently demonstrated that human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) can be differentiated into SSC-like cells³⁹ that express PLZF, a marker for stem and progenitor spermatogonia. This lineage has been shown in several animal models to be capable of re-colonizing the testis as observed by SSC transplant^{16,22}. We recently proposed a two-step concept for utilizing pluripotent stem cells to treat male infertility where sterility was caused by non-genetic factors^{12,13}. We stated that patient-specific pluripotent stem cells could be differentiated into SSCs for transplant into the testis if the somatic environment was intact to restore fertility, or pluripotent stem cells could be differentiated into functional haploid cells for IVF if the somatic environment was unable to support germ cell re-colonization¹². We demonstrated that hESCs and hiPSCs can be differentiated *in vitro* into advanced spermatogenic lineages including acrosin-, transition protein 1-, and protamine 1-positive round spermatids³⁹. While round spermatids have not been successful in fertilizing oocytes in higher order mammals, our results indicate that it is at least feasible to differentiate pluripotent stem cells into haploid spermatids. Improvements in the differentiation strategy could lead to the maturation of round spermatids into elongated spermatids, which are capable of fertilizing an oocyte in IVF clinics or even sperm (Fig. 1). Future potential cures for infertility/sterility could target *in vitro* differentiation into functional spermatids and thus not necessitate testis cell transplantations.

Until recently, most of the major advances involving germ cell differentiation into haploid cells have been in male stem cells. The recent work by Hayashi et al. showed that mouse stem cells could be differentiated in an *in vitro/in vivo* system into oocyte-like cells that are capable of being fertilized by sperm and generating normal progeny⁴⁰. Whether this outstanding achievement by Hayashi et al.⁴⁰ can be adapted for human stem cells remains to be seen, but this advancement is a critical step forward in generating *de novo* oocytes from human iPSCs from female patients rendered sterile by medical interventions, exposure to toxicants, or by premature ovarian failure. The major concept of this work suggested that co-culture of oocyte support cells within the follicle (granulosa cells and theca cells) can shape

the maturation of a PGC derived from pluripotent stem cells into a functional oocyte. Potentially, patient-specific pluripotent stem cells could be differentiated into follicle support cells, as shown with mouse cells⁴¹, and co-cultured with PGCs derived from the same patient-specific pluripotent stem cell line. In theory, this co-culture system could enable investigators to generate *de novo* oocytes from patient-specific pluripotent stem cells (Fig. 2)

Sources of Patient-specific Pluripotent Stem Cells

One of the greatest advancements in the last 10 years in human pluripotent stem cell technology, as evidenced by Dr. Yamanaka being awarded the Nobel Prize, was the ability to reprogram adult somatic cells into embryonic stem-like cells using four factors: *OCT4*, *SOX2*, *KLF4*, and *c-Myc*. The resulting cells were termed induced pluripotent stem cells (iPSCs)^{42–48}. This advance made possible the concept of generating patient-specific pluripotent stem cells in an ethically favorable method. While there have been discrepancies between embryonic stem cells (ESCs) and iPSCs in cell cycle profiles, genomic imprints, and mitochondrial function^{39,49–53}; iPSCs appear to “get it right” upon differentiation, including establishing correct parent-of-origin imprints on at least two loci in haploid spermatids³⁹. With the recently shown ability to generate GMP hiPSCs for potential clinical uses^{54,55}, it may become possible to generate iPSCs from sterile patients. Advances in our protocol to GMP/animal component free conditions combined with the work of Hermann et. al.²² could lead to the first stem cell replacement therapy for male infertility whereby iPSC differentiation into SSC-like cells is followed by transplantation of these SSC-like cells into the patient’s testes to restore fertility. Thus, infertility due to non-genetic root causes could be reversed using no greater starting material than a mere skin biopsy.

Similarly, the work by Hayashi et. al.⁴⁰ further suggest that human iPSCs could potentially be utilized to give rise to *de novo* oocytes for use in IVF clinics to allow sterile women to conceive a child, assuming fertility is solely due to a lack of functional oocytes. There is the concern that iPSCs often carry epigenetic marks similar to the original cell type and thus somewhat impact differentiation. For example, iPSCs derived from blood cells maintain epigenetic marks similar to the original blood cell type and thus differentiate into better blood cells than iPSCs derived from skin tissue⁵⁶. The same problem could exist for *in vitro* derived gametes in that skin fibroblasts might not generate the most functional spermatids. Deriving iPSCs from multiple cell types and then differentiating into gametic lineages is necessary to determine which adult somatic cell type generates the most functional gamete with the most correct parent-of-origin imprints.

Until recently, iPSCs were the only source of human patient-specific stem cells. The “gold standard” of patient-specific stem cells is the generation of somatic cell nuclear transfer-derived embryonic stem cells (SCNT-ESCs). Very recently, Tachibana et. al. demonstrated the ability to generate human SCNT-ESCs from donor human oocytes^{57,58}. The ability to use an oocyte environment to reprogram a somatic nucleus is more clinically favorable to generating iPSCs. iPSC derivations rely on the use of exogenously expressed oncogenes (*OCT4*, *SOX2*, *KLF4*, *CMYC*) to initiate cellular reprogramming into a pluripotent state. Even if these oncogenes are excised from the genome after reprogramming, there is still a

concern as to whether iPSCs possess an oncogenic potential upon transplantation. However, the ethical concerns and low efficiency surrounding SCNT-ESCs make iPSCs a far more attractive option for patient-specific stem cells. Whether SCNT-ESCs pair more closely with hESCs than iPSCs in parent-of-origin genomic imprints, cell cycle progression, mitochondrial function, among others, remains to be examined as SCNT-ESC derivations have only recently just been demonstrated in humans. Perhaps SCNT-ESCs will possess a greater ability to differentiate into more functional adult somatic and germ cells than iPSCs because SCNT-ESCs will not possess the “remnant” imprints observed in iPSCs, thereby providing a more complete reprogramming.

Non-human Primate Animal Modeling is Essential for Progressing Stem Cell Treatments for Infertility to the Clinic

Many current animal models for infertility center on murine models. While informative, murine models for gametogenesis are distinctly different from human and non-human primate, especially with regards to spermatogenesis⁵⁹. The advances by Herman et. al. show the ability of non-human primate SSCs to recolonize a sterilized testis and generate functional sperm²². To examine whether germline stem cells are dispensable and that pluripotent stem cells can be utilized to restore fertility in non-human primates sterilized by chemotherapies, SCNT-ESCs and iPSCs need to be derived from non-human primates prior to and post chemotherapy exposure (to ensure that chemotherapeutics do not negatively impact the ability to derive pluripotent stem cells capable of differentiating into germ cell lineages). SSC-like cells would need to be derived³⁹ and then transplanted into the testis to examine whether SSCs from SCNT-ESCs or iPSCs are better at recolonizing the testis, undergoing spermatogenesis, and generating the most functional haploid spermatids. Similarly, *in vitro* differentiation would need to be carried out to the haploid spermatid stage followed by ICSI (intracytoplasmic sperm(ati)d injection) into a non-human primate oocyte to determine which “patient-specific” cell source better supports oocyte activation and viable fetal development thus demonstrating whether are more capable of generating functional male gametes. Sperm derived from transplants and spermatids derived from *in vitro* differentiation will need to be assessed for correct genomic imprints on all parent-of-origin imprinted genes to ensure that resulting offspring are not in danger of inheriting a debilitating parent-of-origin imprinting disorder such as Prader-Willi. Spermatids and sperm will also need to be assessed for the ability to fertilize an oocyte, develop to the blastocyst stage, and support viable fetal development leading to live births. Likewise, long-term health and reproductive outcomes will have to be assessed.

For the female side, *in vitro* oogenesis has not been currently described in primates (see Fig. 2). However, Hayashi et. al.⁴⁰ pioneering work might be adaptable to non-human primates to determine whether co-culture of PGCs and follicle support cells can be matured *in vivo* by injecting in the kidney capsule or, more preferably, under the skin^{60,61}. Oocytes derived in this manner will have to be assessed for correct parent-of-origin imprints and for functionality by IVF with donor non-human primate sperm followed by development to the blastocyst stage. All of these proposed experiments should be conducted with SCNT-ESCs and iPSCs to determine which cell source is preferable for generating functional oocytes.

Finally, for male and female gametes derived from pluripotent stem cells, the generation of a healthy progeny is the ultimate goal. Experiments absolutely must be conducted at the non-human primate level to determine whether implanted blastocysts (derived as described above for either male or female pluripotent stem cell derived gametes) can develop *in utero* correctly resulting in a healthy, normal offspring. Further examinations on post-natal development would also have to be conducted to ensure there are no cognitive and aging deficits. Addressing such questions/concerns are especially critical prior to attempting the use of pluripotent stem cell-derived gametes in the clinic to restore patients' fertility in patients rendered sterile by medical treatments, exposure to environmental or industrial toxicants, or injury.

Conclusion

Stem cell treatments are starting to become more prevalent in clinical trials, with perhaps the first biggest advancement being the use of retinal pigment epithelial cells derived from hESCs to restore vision in patients with Macular Degeneration⁶². However, patient-specific cells will be required for germ cell replacement therapies at the clinical level. While the clinical applications for *in vitro* derived patient-specific gametes are still years away, the advancements being made in *in vitro* differentiation methods are making the possibility of using a patient's own somatic cells for generating functional gametes after she/he has been rendered sterile a true reality.

References

1. Bahadur G. Fertility issues for cancer patients. *Molecular and cellular endocrinology*. 2000 Nov 27; 169(1–2):117–122. [PubMed: 11155943]
2. Wallace WH. Oncofertility and preservation of reproductive capacity in children and young adults. *Cancer*. 2011 May 15; 117(10 Suppl):2301–2310. [PubMed: 21523750]
3. Woodruff TK. The Oncofertility Consortium--addressing fertility in young people with cancer. *Nature reviews. Clinical oncology*. 2010 Aug; 7(8):466–475.
4. Wyns C, Curaba M, Petit S, et al. Management of fertility preservation in prepubertal patients: 5 years' experience at the Catholic University of Louvain. *Hum Reprod*. 2011 Apr; 26(4):737–747. [PubMed: 21227939]
5. Wyns C, Curaba M, Vanabelle B, Van Langendonck A, Donnez J. Options for fertility preservation in prepubertal boys. *Hum Reprod Update*. 2010 May-Jun; 16(3):312–328. [PubMed: 20047952]
6. Jahnukainen K, Ehmcke J, Hou M, Schlatt S. Testicular function and fertility preservation in male cancer patients. *Best practice & research. Clinical endocrinology & metabolism*. 2011 Apr; 25(2): 287–302. [PubMed: 21397199]
7. Keros V, Hultenby K, Borgstrom B, Fridstrom M, Jahnukainen K, Hovatta O. Methods of cryopreservation of testicular tissue with viable spermatogonia in pre-pubertal boys undergoing gonadotoxic cancer treatment. *Hum Reprod*. 2007 May; 22(5):1384–1395. [PubMed: 17259225]
8. Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. *J Clin Oncol*. 2010 Nov 10; 28(32):4831–4841. [PubMed: 20458029]
9. Orwig KE, Schlatt S. Cryopreservation and transplantation of spermatogonia and testicular tissue for preservation of male fertility. *J Natl Cancer Inst Monogr*. 2005; (34):51–56. [PubMed: 15784824]
10. Deutsch MA, Kaczmarek I, Huber S, et al. Sirolimus-associated infertility: case report and literature review of possible mechanisms. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2007 Oct; 7(10):2414–2421.

11. Skrzypek J, Krause W. Azoospermia in a renal transplant recipient during sirolimus (rapamycin) treatment. *Andrologia*. 2007 Oct; 39(5):198–199. [PubMed: 17714220]
12. Easley CA, Phillips BT, Wu G, Schatten GP, Simerly CR. Clinical Implications of Human Spermatogenesis Initiation in Vitro. *J Med Sci*. 2012; 32(6):257–263.
13. Easley, CA; Simerly, CR.; Schatten, G. Stem cell therapeutic possibilities: future therapeutic options for male-factor and female-factor infertility? *Reproductive biomedicine online*. 2013 Jul; 27(1):75–80. [PubMed: 23664220]
14. Schlegel PN. Evaluation of male infertility. *Minerva ginecologica*. 2009 Aug; 61(4):261–283. [PubMed: 19745794]
15. Clark AT, Phillips BT, Orwig KE. Fruitful progress to fertility: male fertility in the test tube. *Nature medicine*. Dec; 2011 17(12):1564–1565.
16. Brinster RL. Male germline stem cells: from mice to men. *Science*. 2007 Apr 20; 316(5823):404–405. [PubMed: 17446391]
17. Brinster RL, Avarbock MR. Germline transmission of donor haplotype following spermatogonial transplantation. *Proc Natl Acad Sci U S A*. 1994 Nov 22; 91(24):11303–11307. [PubMed: 7972054]
18. Brinster RL, Zimmermann JW. Spermatogenesis following male germ-cell transplantation. *Proc Natl Acad Sci U S A*. 1994 Nov 22; 91(24):11298–11302. [PubMed: 7972053]
19. Nagano M, Avarbock MR, Leonida EB, Brinster CJ, Brinster RL. Culture of mouse spermatogonial stem cells. *Tissue Cell*. 1998 Aug; 30(4):389–397. [PubMed: 9787472]
20. Oatley JM, Brinster RL. Spermatogonial stem cells. *Methods Enzymol*. 2006; 419:259–282. [PubMed: 17141059]
21. Ryu BY, Orwig KE, Avarbock MR, Brinster RL. Stem cell and niche development in the postnatal rat testis. *Dev Biol*. 2003 Nov 15; 263(2):253–263. [PubMed: 14597200]
22. Hermann BP, Sukhwani M, Winkler F, et al. Spermatogonial stem cell transplantation into rhesus testes regenerates spermatogenesis producing functional sperm. *Cell stem cell*. 2012 Nov 2; 11(5):715–726. [PubMed: 23122294]
23. Hermann BP, Sukhwani M, Salati J, Sheng Y, Chu T, Orwig KE. Separating spermatogonia from cancer cells in contaminated prepubertal primate testis cell suspensions. *Hum Reprod*. 2011 Dec 5; 26(12):3222–3231. [PubMed: 22016413]
24. Buaas FW, Kirsh AL, Sharma M, et al. Plzf is required in adult male germ cells for stem cell self-renewal. *Nature genetics*. 2004 Jun; 36(6):647–652. [PubMed: 15156142]
25. Eguizabal C, Montserrat N, Vassena R, et al. Complete meiosis from human induced pluripotent stem cells. *Stem Cells*. 2011 Aug; 29(8):1186–1195. [PubMed: 21681858]
26. Geijsen N, Horoschak M, Kim K, Gribnau J, Eggan K, Daley GQ. Derivation of embryonic germ cells and male gametes from embryonic stem cells. *Nature*. 2004 Jan 8; 427(6970):148–154. [PubMed: 14668819]
27. Kee K, Angeles VT, Flores M, Nguyen HN, Reijo Pera RA. Human DAZL, DAZ and BOULE genes modulate primordial germ-cell and haploid gamete formation. *Nature*. 2009 Nov 12; 462(7270):222–225. [PubMed: 19865085]
28. Kee K, Gonsalves JM, Clark AT, Pera RA. Bone morphogenetic proteins induce germ cell differentiation from human embryonic stem cells. *Stem Cells Dev*. 2006 Dec; 15(6):831–837. [PubMed: 17253946]
29. Ko K, Huebner K, Mueller-Keuker J, Schoeler HR. In vitro derivation of germ cells from embryonic stem cells. *Front Biosci*. 2010; 15:46–56.
30. Nayernia K, Nolte J, Michelmann HW, et al. In vitro-differentiated embryonic stem cells give rise to male gametes that can generate offspring mice. *Dev Cell*. 2006 Jul; 11(1):125–132. [PubMed: 16824959]
31. Panula S, Medrano JV, Kee K, et al. Human germ cell differentiation from fetal- and adult-derived induced pluripotent stem cells. *Human molecular genetics*. 2011 Feb 15; 20(4):752–762. [PubMed: 21131292]
32. Park TS, Galic Z, Conway AE, et al. Derivation of primordial germ cells from human embryonic and induced pluripotent stem cells is significantly improved by coculture with human fetal gonadal cells. *Stem Cells*. 2009 Apr; 27(4):783–795. [PubMed: 19350678]

33. Teramura T, Takehara T, Kawata N, et al. Primate embryonic stem cells proceed to early gametogenesis in vitro. *Cloning and stem cells*. Summer;2007 9(2):144–156. [PubMed: 17579549]
34. Tilgner K, Atkinson SP, Golebiewska A, Stojkovic M, Lako M, Armstrong L. Isolation of primordial germ cells from differentiating human embryonic stem cells. *Stem Cells*. 2008 Dec; 26(12):3075–3085. [PubMed: 18802037]
35. Toyooka Y, Tsunekawa N, Akasu R, Noce T. Embryonic stem cells can form germ cells in vitro. *Proc Natl Acad Sci U S A*. 2003 Sep 30; 100(20):11457–11462. [PubMed: 14504407]
36. Yamauchi K, Hasegawa K, Chuma S, Nakatsuji N, Suemori H. In vitro germ cell differentiation from cynomolgus monkey embryonic stem cells. *PloS one*. 2009; 4(4):e5338. [PubMed: 19399191]
37. Hayashi K, Ohta H, Kurimoto K, Aramaki S, Saitou M. Reconstitution of the Mouse Germ Cell Specification Pathway in Culture by Pluripotent Stem Cells. *Cell*. 2011 Aug 19; 146:1–14.
38. Zhao XY, Li W, Lv Z, et al. Viable fertile mice generated from fully pluripotent iPS cells derived from adult somatic cells. *Stem Cell Rev*. 2010 Sep; 6(3):390–397. [PubMed: 20549390]
39. Easley, CAT; Phillips, BT.; McGuire, MM., et al. Direct differentiation of human pluripotent stem cells into haploid spermatogenic cells. *Cell reports*. 2012 Sep 27; 2(3):440–446. [PubMed: 22921399]
40. Hayashi K, Ogushi S, Kurimoto K, Shimamoto S, Ohta H, Saitou M. Offspring from oocytes derived from in vitro primordial germ cell-like cells in mice. *Science*. 2012 Nov 16; 338(6109): 971–975. [PubMed: 23042295]
41. Kang Y, Cheng MJ, Xu CJ. Secretion of oestrogen from murine-induced pluripotent stem cells co-cultured with ovarian granulosa cells in vitro. *Cell Biol Int*. 2011 Sep; 35(9):871–874. [PubMed: 21410434]
42. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. *Nature*. 2007 Jul 19; 448(7151):313–317. [PubMed: 17554338]
43. Park IH, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. *Cell*. 2008 Sep 5; 134(5):877–886. [PubMed: 18691744]
44. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. *Nature*. 2008 Jan 10; 451(7175):141–146. [PubMed: 18157115]
45. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*. 2007 Nov 30; 131(5):861–872. [PubMed: 18035408]
46. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006 Aug 25; 126(4):663–676. [PubMed: 16904174]
47. Yamanaka S. A fresh look at iPS cells. *Cell*. 2009 Apr 3; 137(1):13–17. [PubMed: 19345179]
48. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. *Science*. 2007 Dec 21; 318(5858):1917–1920. [PubMed: 18029452]
49. Carey BW, Markoulaki S, Hanna JH, et al. Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. *Cell stem cell*. 2011 Dec 2; 9(6):588–598. [PubMed: 22136932]
50. Christodoulou C, Longmire TA, Shen SS, et al. Mouse ES and iPS cells can form similar definitive endoderm despite differences in imprinted genes. *The Journal of clinical investigation*. 2011 Jun; 121(6):2313–2325. [PubMed: 21537085]
51. Momcilovic O, Knobloch L, Fornasaglio J, Varum S, Easley C, Schatten G. DNA damage responses in human induced pluripotent stem cells and embryonic stem cells. *PloS one*. 2010; 5(10):e13410. [PubMed: 20976220]
52. Pick M, Stelzer Y, Bar-Nur O, Mayshar Y, Eden A, Benvenisty N. Clone- and gene-specific aberrations of parental imprinting in human induced pluripotent stem cells. *Stem Cells*. Nov; 2009 27(11):2686–2690. [PubMed: 19711451]
53. Varum S, Rodrigues AS, Moura MB, et al. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. *PloS one*. 2011; 6(6):e20914. [PubMed: 21698063]
54. Karumbayaram S, Lee P, Azghadi SF, et al. From skin biopsy to neurons through a pluripotent intermediate under Good Manufacturing Practice protocols. *Stem cells translational medicine*. 2012 Jan; 1(1):36–43. [PubMed: 23197638]

55. Okita K, Yamakawa T, Matsumura Y, et al. An Efficient Non-viral Method to Generate Integration-Free Human iPS Cells from Cord Blood and Peripheral Blood Cells. *Stem Cells*. 2012 Nov 29.
56. Kim K, Doi A, Wen B, et al. Epigenetic memory in induced pluripotent stem cells. *Nature*. 2010 Sep 16; 467(7313):285–290. [PubMed: 20644535]
57. Tachibana M, Amato P, Sparman M, et al. Human embryonic stem cells derived by somatic cell nuclear transfer. *Cell*. Jun 6; 2013 153(6):1228–1238. [PubMed: 23683578]
58. Trounson A, DeWitt ND. Pluripotent stem cells from cloned human embryos: success at long last. *Cell stem cell*. 2013 Jun 6; 12(6):636–638. [PubMed: 23746970]
59. Schlatt S, Rosiepen G, Weinbauer GF, Rolf C, Brook PF, Nieschlag E. Germ cell transfer into rat, bovine, monkey and human testes. *Hum Reprod*. Jan; 1999 14(1):144–150. [PubMed: 10374111]
60. Oktay K, Buyuk E, Veeck L, et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. *Lancet*. 2004 Mar 13; 363(9412):837–840. [PubMed: 15031026]
61. Oktay K, Economos K, Kan M, Rucinski J, Veeck L, Rosenwaks Z. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. *JAMA : the journal of the American Medical Association*. 2001 Sep 26; 286(12):1490–1493.
62. Pan CK, Heilweil G, Lanza R, Schwartz SD. Embryonic stem cells as a treatment for macular degeneration. *Expert opinion on biological therapy*. 2013 Aug; 13(8):1125–1133. [PubMed: 23705996]

Figure 1. *In vitro* spermatogenesis

Diagram depicting *in vitro* spermatogenesis whereby patient-specific pluripotent stem cells could be differentiated into spermatogonia for transplant into a sterile testis in which the somatic environment is intact or differentiated further into an advanced spermatid or sperm capable of fertilizing an oocyte through ICSI. Type Ad (A-Dark) represents the slow-dividing SSC populations, and Type Ap (A-Pale) represents the differentiating SSC population. B type spermatogonia represent progenitor spermatogonia. Differentiating human male ESCs and iPSCs in mouse SSC culture conditions mimics aspects of this diagram as PLZF-positive stem and progenitor spermatogonia, primary and secondary spermatocytes, and round spermatids are all generated *in vitro*.

Figure 2. *In vitro* oogenesis

Diagram depicting *in vitro* oogenesis whereby patient-specific pluripotent stem cells could be differentiated into primordial germ cells (PGCs) and co-cultured with follicle support cells derived from the same patient-specific pluripotent stem cells. *In vitro* maturation of the follicle would need to be performed to generate a resulting product capable of being fertilized by standard IVF methods.